Cerebral to pay nearly $3.7M over controlled substance prescribing practices

Phase IIa da­ta for Struc­ture Ther­a­peu­tics’ oral GLP-1 drug can­di­date for type 2 di­a­betes and obe­si­ty best­ed an­a­lyst ex­pec­ta­tions on safe­ty and tol­er­a­bil­i­ty, but low­er-than-hoped-for

NEW YORK — Al­ny­lam’s sur­prise change to the analy­sis plan for one of this year’s most an­tic­i­pat­ed clin­i­cal tri­al read­outs set off a flur­ry of